Mylan announced that its shareholders approved its purchase of an Abbott Laboratories business and its tax-reducing move to the Netherlands. The company also said European Union regulators cleared the deal, which Mylan values at about $5.3 billion.
Abbott Laboratories has reported fourth-quarter earnings of $905 million. On a per-share basis,...
Zoetis today announced an agreement to purchase animal health assets of Abbott for a purchase...
Abbott Laboratories said Thursday that its board approved spending up to $3 billion to buy back the health conglomerate's stock.
New details from two studies reveal more side effects from niacin, a drug that hundreds of thousands of Americans take for cholesterol problems and general heart health. Some prominent doctors say the drug now seems too risky for routine use.
Abbott Laboratories said that its second-quarter profit declined 2.1 percent, hampered by higher taxes. Adjusted profit and revenue topped Wall Street expectations, however, and the company boosted its full-year earnings forecast.
Mylan said Monday that the deal will diversify and expand its business outside the U.S. The combined company will be organized in the Netherlands, which will help reduce its tax expenses, while maintaining its headquarters near Pittsburgh.
Abbott has announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer. Under the terms of the agreement, Abbott will acquire Limited Liability Company Garden Hills, the holding company that currently owns a controlling interest in Veropharm, for between 13.6 billion rubles and 17 billion rubles (or a range of approximately $395 million to $495 million U.S. dollars)
Abbott today announced a definitive agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence.
Abbott Laboratories is closing one of its manufacturing plants in the Puerto Rico town of Barceloneta next year, delivering another blow to the U.S. territory's once-thriving pharmaceutical sector, officials said Thursday.
A multibillion dollar case between two giant pharmaceutical companies grappling over arcane antitrust issues has unexpectedly turned into a gay rights legal imbroglio that raises questions over whether lawyers can bounce potential jurors solely based on their sexual orientation.
New York's comptroller, who oversees the state's $160 billion pension fund, says he will keep fighting to use the power of massive investments to hold corporate executives accountable for mistakes that could affect the bottom line.
Abbott Laboratories has announced it will pay a combined $560M to acquire two privately-held companies focused on coronary implants and laser-assisted eye surgery.
Abbott Laboratories said Friday that it plans to buy back up to $3 billion of its common stock, replacing a finished $5 billion program that began before the health care company separated from its drug business. Abbott makes generic drugs, medical implants and nutritional formula. It spun off its...
A group of Jefferies & Co. analysts said yesterday that drug companies are putting more emphasis on restructuring and spinning off parts of their business, and that those moves will be a critical factor in stock performance in 2013 and 2014.
U.S. health regulators are warning doctors and women of child-bearing age that half-a-dozen medications used to treat migraine headaches can decrease children's intelligence if taken while their mothers are pregnant. The Food and Drug Administration said Monday that the drugs, including Depakote and Depacon, should never be taken by pregnant women for the prevention of migraine headaches.
Abbott Laboratories said today its first-quarter net income slid as the year-earlier period got a boost from discontinued operations. However, earnings from continuing operations climbed more than 4 percent on sales of the company's nutritionals and diagnostic tests. Sales of those products helped offset declines in medical devices, which fell more than 4 percent.
Abbott Laboratories is recalling its FreeStyle InsuLinx Blood Glucose Meters after finding that they display and store incorrect test results for dangerously high blood sugar levels. The company says the meters will display and store readings for blood glucose levels of 1,024 milligrams per deciliter or higher at much lower levels.
The board of directors of AbbVie Inc. declared a quarterly cash dividend and also authorized a share repurchase program of up to $1.5 billion of the Company's outstanding common stock. The cash dividend of $0.40 per share is payable May 15, 2013 to stockholders of record at the close of business on April 15, 2013.
AbbVie delivered strong sales growth with its marketed pharmaceutical products in 2012. The proprietary pharmaceutical segment of Abbott, representing the majority of AbbVie's revenue, grew more than 8 percent globally on an operational basis.
Sucampo Pharmaceuticals, Inc. today announced that its subsidiary, Sucampo AG, has received a $15 million milestone payment from Abbott’s subsidiary, Abbott Japan Co., Ltd., pursuant to the existing license, commercialization, and supply agreement between Sucampo Pharma Ltd. (SPL), SPI’s subsidiary, and Abbott.
Abbott Board of Directors Approves Separation of AbbVie and Declares Special Dividend Distribution of AbbVie StockNovember 29, 2012 3:02 am | News | Comments
Abbott announced today that its board of directors has approved the separation of its research-based pharmaceuticals business, which will be known as AbbVie Inc.
Sucampo Pharmaceuticals, Inc. and Abbott today announced the availability of AMITIZA® (lubiprostone) in Japan, a prescription medicine for the treatment of chronic constipation not caused by organic diseases.
Abbott announced Tuesday that it is initiating a late-stage trial program for its three direct acting antivirals (DAAs), ABT-450, ABT-267 and ABT-333, in patients with hepatitis C virus (HCV) genotype 1.
Abbott on Monday announced that Humira (adalimumab) was associated with significant improvements in physical function and health-associated quality of life in a Phase III trial involving patients with active non-radiographic axial spondyloarthritis (NRAS).
Shares of Abbott Laboratories slid Thursday because the company's partner on a potential kidney disease drug is stopping a late-stage study due to safety concerns.
WASHINGTON (AP) — Drug and medical device maker Abbott Laboratories reported a higher third-quarter profit Wednesday, edging past analyst expectations, even as revenue slipped. The company, which is in the process of spinning off some of its businesses, also laid off 550 employees globally and said it plans to eliminate several hundred additional positions next year.
Abbott announced today that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVaxTM), an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus (CMV) reactivation in transplant patients.
- Page 1